DNA hypomethylation is one of the major epigenetic alterations in human cancers. We have previously shown that genes identified as hypomethylated in pancreatic cancer are expressed in pancreatic cancer cell lines, but not in normal pancreatic ductal epithelium and can be reexpressed in nonexpressing cells using 'epigenetic modifying agents' such as DNA methyltransferase inhibitors. To identify additional targets for aberrant hypomethylation in pancreatic cancer, we used oligonucleotide microarrays to screen for genes that displayed expression patterns associated with hypomethylation. This analysis identified a substantial number of candidates including previously reported hypomethylated genes. A subset of eight genes were selected for further methylation analysis, and two cancer-related genes, maspin and S100P, were found to be aberrantly hypomethylated in a large fraction of pancreatic cancer cell lines and primary pancreatic carcinomas. Combined treatment with 5-aza-2 0 -deoxycytidie and trichostatin A resulted in synergistic induction of maspin and S100P mRNA in MiaPaCa2 cells where both genes were methylated. Furthermore, there was an inverse correlation between methylation and mRNA expression level for maspin and S100P in a large panel of pancreatic cancer cell lines. We also found a significant difference in the methylation patterns of maspin and two previously identified hypomethylated genes (trefoil factor 2 and lipocalin 2) between pancreatic and breast cancer cell lines, suggesting cancer-type specificity for some hypomethylation patterns. Thus, our present results confirm that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer, and suggest that gene expression profiling may help to identify potential targets affected by this epigenetic alteration.
Introduction
Pancreatic cancer is now recognized as both a genetic and an epigenetic disease characterized by mutations, deletions, amplifications as well as alterations in DNA methylation, including hyper-and hypomethylation of genes critical for tumor development and progression (Goggins et al., 1999; Ueki et al., 2000; Ueki et al., 2001; Fukushima et al., 2002; Rosty et al., 2002; Fukushima et al., 2003; Matsubayashi et al., 2003; Sato et al., 2003a-d) . Aberrant hypermethylation of promoter CpG islands is closely linked to gene silencing and loss of tumor suppressor function in cancer (Jones and Baylin, 2002) . On the other hand, DNA hypomethylation at specific CpG sites is often associated with activation of affected genes (Ehrlich, 2002) . Several previous studies have described a correlation between site-specific hypomethylation and increased expression of cancerrelated genes such as MAGE (De Smet et al., 1996) , S100A4 , synuclein g (Gupta et al., 2003) , urokinase-type plasminogen activator (uPA) (Guo et al., 2002; Pakneshan et al., 2003) , matrix metalloproteinases (MMPs) (Sato et al., 2003c) , and others (Sato et al., 2003d) , although the cause of such hypomethylation is not yet fully understood. Identification of genes that are hypomethylated in a cancer-specific manner may provide further insights into the role of aberrant gene hypomethylation in tumorigenesis. More importantly, because DNA hypomethylation has been considered a reversible biological modification, such genes may represent novel targets for cancer therapy (Yao et al., 2003) .
Genome-wide DNA hypomethylation has been associated with genetic instability (Chen et al., 1998) , and a recent study provided evidence for direct involvement of global hypomethylation in tumorigenesis (Gaudet et al., 2003) . Little is known about the biological significance of site-specific hypomethylation in cancer, but the hypomethylation-associated activation of potential cancer-promoting genes, particularly those involved in tumor invasion and metastasis, might contribute to the malignant phenotype. In this respect, cancer therapies using DNA methyltransferase and histone deacetylase inhibitors could lead to reactivation of these genes when silenced by methylation and, in some cases, accelerate tumor progression. In fact, we and other investigators have shown that treatment with a DNA methyltransferase inhibitor results in upregulation of invasion-promoting genes (including MMPs and uPA), thereby leading to an increased invasiveness in certain cancer cell lines (Guo et al., 2002; Pakneshan et al., 2003; Sato et al., 2003c) .
In a previous study, we were able to identify multiple genes that were hypomethylated and overexpressed in pancreatic cancer by extensively analysing the methylation status of a large panel of genes with differing expression profiles (Sato et al., 2003d) . In an attempt to discover additional targets affected by aberrant DNA hypomethylation in pancreatic cancer, we used highthroughput oligonucleotide microarrays to screen for genes that are characterized by a hypomethylated-genespecific expression pattern, which has emerged during the previous analysis.
Materials and methods

Cell lines, xenografts, and tissue samples
Human pancreatic cancer cell lines AsPC1, BxPC3, Capan1, Capan2, CFPAC1, Hs766T, MiaPaCa2, Panc1, and Su8686 were obtained from the ATCC (Rockville, MD, USA) and Colo357 from ECACC (Salisbury, UK). Low-passage pancreatic carcinoma cell lines (PL) were generously provided by Dr Elizabeth Jaffee (The Johns Hopkins Medical Institutions, Baltimore, MD, USA). Frozen tissues of bulk normal pancreas were obtained from surgical specimens resected at The Johns Hopkins Medical Institutions. In five cases, normal duct epithelial cells were selectively microdissected from the frozen sections using a laser-capture microdissection (LCM) system (PixCell II, Arcturus, Mountain View, CA). Pancreatic cancer xenografts were established from surgically resected primary pancreatic carcinomas, and 34 xenografts were randomly selected for this study. Pancreatic cancer cells were also microdissected by LCM from seven primary pancreatic adenocarcinoma samples. DNA samples from breast cancer cell lines were generously provided by Dr Mieke Schutte (University Hospital Rotterdam, The Netherlands).
Treatment with 5-aza-2 0 -deoxycytidine (5Aza-dC)and/or trichostatin A (TSA) Cells were treated with 5Aza-dC (Sigma, St Louis, MO, USA) and with TSA (Sigma), either alone or in combination, as described previously (Sato et al., 2003b) .
Oligonucleotide array hybridization and data analysis
Sample preparation for oligonucleotide microarray was performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA), as described previously (Sato et al., 2003b ). The fragmented cRNA was then hybridized to the Human Genome U133A chips (Affymetrix) with 18 462 unique gene/EST transcripts at 451C for 16 h. The probes were then scanned using a laser scanner, and signal intensity for each transcript (background-subtracted and adjusted for noise) and detection call (present, absent, or marginal) were determined using Microarray Suite Software 5.0 (Affymetrix).
Methylation-specific PCR (MSP)
Genomic DNA was isolated from the cell lines and frozen tissues using a DNA isolation kit (QIAGEN, Valencia, CA, USA) and subjected to sodium bisulfite treatment. The methylation status of each gene was also determined by MSP, as previously described (Herman et al., 1996) . Primers were designed to detect the sequence differences between methylated and unmethylated DNA as a result of bisulfite modification, and each primer pair contained at least three CpG sites to provide optimal specificity. Since knowledge of the regulatory regions of many of the genes overexpressed in pancreatic cancer is not known, we decided to characterize the methylation status of CpG's within a few hundred base pairs of the transcriptional start site, where CpG methylation has been implicated in transcriptional silencing (Bird, 2002) . The primer sequences for each gene are available upon request.
Semiquantitative reverse transcription-PCR (RT-PCR)
RT-PCR was performed with primers for maspin or S100P (the primer sequences are available upon request) and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in duplex reactions. The range of linear amplification for each gene and the GAPDH gene was examined with serial PCR cycles, and the optimal PCR cycles were determined. The relative intensity of mRNA expression for each sample was then corrected for variable RNA recovery using the corresponding GAPDH mRNA measurement as a surrogate for total mRNA.
Statistical analysis
Statistical analysis was performed using Mann-Whitney U nonparametric test, Fisher's exact probability test, or Spearman's rank correlation. Differences were considered significant at Po0.05.
Results
Identification of candidate targets for hypomethylation in pancreatic cancer using oligonucleotide microarrays
In our previous study, we have noted that genes identified as hypomethylated in pancreatic cancer are characterized by having a specific gene expression, that is, expressed in pancreatic cancer cell lines but not in normal pancreatic ductal epithelium, expression that can be reactivated by 'epigenetic modifying agents' (DNA methyltransferase inhibitor (5Aza-dC) and/or histone deacetylase inhibitors (TSA)) (Sato et al., 2003d) . In an attempt to identify additional targets for aberrant hypomethylation in pancreatic cancer, we analysed Affymetrix U133A oligonucleotide microarray data to screen for genes that displayed the aforementioned expression pattern. We analysed the expression data from five pancreatic cancer cell lines (AsPC1, CFPAC1, Hs766T, MiaPaCa2, and Panc1) and two microdissected normal pancreatic ductal epithelial samples.
We first filtered genes whose expression value displayed the greatest variation across all the five pancreatic cancer cell lines (s.d./mean 41) and which were overexpressed (called present and signal intensity 4200) in at least one of these cell lines. This analysis identified 1485 transcripts that are likely to be variably expressed in pancreatic cancer cell lines (e.g. overexpressed in some pancreatic cancer cell lines but not expressed in others). Among the 1485 transcripts identified, 392 were found to be induced at threefold or greater in any of the four pancreatic cancer cell lines (AsPC1, Hs766T, MiaPaCa2, and Panc1) after combined treatment with 5Aza-dC and TSA. Finally, we excluded the transcripts whose expression was detectable (called present) in the microdissected normal pancreatic ductal epithelial samples, leaving 218 transcripts identified as having a gene expression pattern associated with hypomethylation (full list of transcripts is available at our website (http://www.pathology2.jhu.edu/pancreas/hypo)). This list included several genes that have been reported to be overexpressed in pancreatic cancer, such as cysteine-rich protein 1 (CRIP1) (Ryu et al., 2002) , decay accelerating factor for complement (CD55) (Iacobuzio-Donahue et al., 2003; Logsdon et al., 2003) , maspin/SERPINB5 (Maass et al., 2001) , S100 calcium-binding protein P (S100P) (Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003) , and tissue-type plasminogen activator (PLAT) (Diaz et al., 2002; Ryu et al., 2002) . Notably, genes previously reported to be hypomethylated in cancer (including aglobin (Feinberg and Vogelstein, 1983) and MAGE-1 (De Smet et al., 1996) ) as well as genes we recently identified as hypomethylated and overexpressed in pancreatic cancer (mesothelin and lipocalin2 (Sato et al., 2003d) ) were also included in this list, supporting the utility of our screening approach.
Methylation analysis of selected genes by methylation-specific PCR
A subset of eight genes that have been reported to be cancer-associated or considered functionally important were selected from the list of 218 transcripts. These genes were BCL2-interacting killer (BIK), CD55, FBJ murine osteosarcoma viral oncogene homolog B (FOSB), maspin, S100P, PLAT, stanniocalcin 1 (STC1), and uridine phosphorylase (UP). Using MSP, we first determined the methylation status of these eight genes in bulk normal pancreatic tissues. Of these eight genes, four genes (BIK, CD55, FOSB, and UP) were completely unmethylated, two (PLAT and STC1) were partially methylated, and the remaining two (maspin and S100P) were predominantly methylated in normal pancreas. The two genes (maspin and S100P) that harbored predominant methylation in normal pancreas were then subjected to further investigation.
The maspin promoter has a relatively CpG-rich sequence, which meets the criteria of a CpG island (Gardiner-Garden and Frommer, 1987; Takai and Jones, 2002) , while S100P contains less CpG dinucleotides within its 5 0 region ( Figure 1a ). As normal pancreas includes different cell types (such as acinar, islet, and ductal cells), the origin of the methylated alleles was uncertain from the MSP analysis of bulk normal pancreas. We therefore analysed the methylation status of maspin and S100P in a panel of five laser-capture microdissected normal pancreatic ductal epithelial samples. MSP revealed that maspin and S100P were nearly completely methylated in these LCM-microdissected ductal cells (Figure 1b) . Thus, these findings suggest that methylation of 5 0 CpG sites at maspin and S100P is a normal event in pancreatic ductal epithelium where the expression of these genes is absent. Hypomethylation of maspin and S100P in pancreatic cancer N Sato et al
Maspin and S100P were then tested for hypomethylation in a panel of 23 pancreatic cancer cell lines. In contrast to the predominant methylation in normal pancreatic ductal epithelium, maspin was completely unmethylated in 20 (87%) of the 23 cell lines, indicating aberrant hypomethylation (Figure 1c) . Similarly, hypomethylation (amplification of only unmethylated alleles) of S100P was detected in 13 (57%) of the 23 pancreatic cancer cell lines (Figure 1c) . These findings suggest that hypomethylation of maspin and S100P is a common epigenetic abnormality in pancreatic cancer cell lines.
Correlation between methylation status and mRNA expression level of maspin and S100P in pancreatic cancer cell lines
To determine if DNA methylation and histone deacetylation were involved in the transcriptional regulation of maspin and S100P in pancreatic cancer cells, we examined the mRNA expression of these genes in MiaPaCa2, which harbored methylated maspin and S100P, after treatment with 5Aza-dC and/or TSA. Treatment of MiaPaCa2 cells with 5Aza-dC led to a partial loss of methylation at 5 0 CpG sites of maspin, and TSA treatment alone also induced a slight loss of methylation at this gene locus, as determined by the relative methylation ratio (the relative proportion of methylated alleles against total intensity of unmethylated and methylated alleles) (Figure 2a ). Combined treatment with 5Aza-dC and TSA resulted in further loss of methylation (Figure 2a) . RT-PCR revealed that treatment with 5Aza-dC restored the expression of maspin mRNA, whereas treatment with TSA alone did not. Notably, combined treatment with 5Aza-dC and TSA strongly induced the maspin expression in a synergistic manner (Figure 2b ). Similar results were obtained for S100P (Figure 2a, b) . Together, these findings suggest that DNA methylation and histone deacetylation may be involved in the transcriptional regulation of maspin and S100P.
We next examined the relation between methylation status and mRNA expression of maspin and S100P in a large panel of pancreatic cancer cell lines. Using semiquantitative RT-PCR, we measured relative expression levels of maspin and S100P mRNA in 17 pancreatic cancer cell lines. Overall, abundant mRNA expression of maspin and S100P was detected in many of the pancreatic cancer cell lines tested (Figure 2c) , which is consistent with previous studies that demonstrated overexpression of these genes in pancreatic cancer (Maass et al., 2001; Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003) . The relative expression level of maspin and S100P was significantly higher in cell lines with hypomethylation than in cell lines without hypomethylation (maspin, P ¼ 0.02; S100P, P ¼ 0.03, MannWhitney U test). As the methylation level of S100P appeared to be variable among cell lines as shown by MSP, we further analysed the relationship between the relative methylation ratio and the relative mRNA expression level for S100P. Remarkably, we found a significant inverse correlation between methylation level and mRNA expression in the 17 cell lines (Figure 2d , P ¼ 0.003, Spearmen's rank correlation).
Methylation analysis of maspin and S100P in xenografted and microdissected primary pancreatic carcinoma A previous report described discordance in the extent of aberrant hypermethylation between cultured There is a significant correlation between methylation and expression of S100P (P ¼ 0.0026, Spearmen's rank correlation)
Hypomethylation of maspin and S100P in pancreatic cancer N Sato et al cell lines and primary tumors (Smiraglia et al., 2001) . To test whether the aberrant hypomethylation detected in pancreatic cancer cell lines is also present in primary tumors, we examined the methylation status of maspin and S100P in a series of 34 xenografted primary pancreatic carcinomas. Using MSP, we detected hypomethylation (amplification of only unmethylated templates) in 32 (94%) of 34 xenografts for maspin and in 30 (88%) for S100P (Figure 3a) . We further analysed the methylation status of these two genes in seven primary pancreatic adenocarcinomas, selectively microdissected by LCM. On the basis of the MSP results from microdissected normal pancreatic ductal epithelium demonstrating virtually complete methylation of maspin and S100P, hypomethylation in primary tissues was defined as the relative methylation ratio of 450%. Hypomethylation of maspin and S100P was frequently (86% for maspin and 100% for S100P) detected in these primary pancreatic cancers (Figure 3b ). These findings suggest that hypomethylation of these genes occurs in primary tumors as well as in cancer cell lines.
Differential methylation patterns of maspin, trefoil factor 2, and lipocalin 2 between pancreatic and breast cancer cell lines
Previous studies have described tumor-type-specific patterns of hypermethylation at several genetic loci (Costello et al., 2000; Esteller et al., 2001) . Furthermore, it has been shown that maspin is aberrantly hypermethylated in breast cancer (Domann et al., 2000; Maass et al., 2002) . We therefore analysed the methylation status of maspin and S100P in a panel of B38 breast cancer cell lines to determine whether the observed hypomethylation patterns are specific to pancreatic cancer. In contrast to the high prevalence of hypomethylation at maspin in pancreatic cancer cell lines (20 of 23, 87%), amplification of only unmethylated maspin was detected in 20 (56%) of the 36 breast cancer cell lines tested ( Figure 3c , P ¼ 0.02, Fisher's exact test). By contrast, there was no significant difference in the frequency of cells containing only unmethylated S100P between pancreatic and breast cancer cell lines (57% (13/23) versus 42% (16/38), P ¼ 0.3). To extend our present finding of cancer-type-specific methylation pattern of maspin to other genes, we compared the methylation patterns of two previously identified hypomethylated genes, trefoil factor 2 (TFF2) and lipocalin2 (Sato et al., 2003d) , between pancreatic and breast cancer cell lines. The frequency of hypomethylation (amplification of only unmethylated alleles) of TFF2 was significantly lower in breast cancer cell lines (seven of 40, 18%) than in pancreatic cancer cell lines (13 of 20, 65%, P ¼ 0.0004). Likewise, the frequency of lipocalin2 hypomethylation was significantly lower in breast cancer cell lines (10 of 40, 25%) than in pancreatic cancer cell lines (17 of 20, 85%, Po0.0001). These results support the notion that gene-specific hypomethylation patterns differ between cancers.
Discussion
In the present study, we have used global gene expression profiling to identify novel targets for aberrant hypomethylation in pancreatic cancer. We have successfully identified two genes, maspin and S100P, that have been previously implicated in cancer progression, as frequently hypomethylated in pancreatic cancer. We also showed an inverse correlation between methylation and mRNA expression of maspin and S100P in pancreatic cancer cell lines. The present results further support our previous finding that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer and is commonly associated with overexpression of affected genes. Recently, microarray-based approaches have been used to screen for genes affected by aberrant hypermethylation in cancers. For example, Suzuki et al. (2002) used a cDNA microarray-based approach to Hypomethylation of maspin and S100P in pancreatic cancer N Sato et al study the gene expression profiles in a colorectal cancer cell line treated with 5Aza-dC and/or TSA, and successfully identified a number of genes harboring CpG island hypermethylation in colorectal cancer cell lines and in primary tumors. We have also identified multiple genes that are aberrantly hypermethylated in pancreatic cancer using oligonucleotide microarrays (Sato et al., 2003b) . Our present study suggests that gene expression profiling could be used to identify novel target genes affected by DNA hypomethylation as well as those affected by hypermethylation in human cancers. Since our screening approach is based on the expression profiles from a panel of pancreatic cancer cell lines, one concern is that expression patterns and methylation changes of some could be the result of prolonged culturing of these cell lines. Furthermore, many genes have been reported to be induced by 5Aza-dC treatment independent of the methylation status of their 5 0 CpGs (Soengas et al., 2001; Zhu et al., 2001; Liang et al., 2002; Suzuki et al., 2002; Sato et al., 2003b) . Therefore, it is important to confirm such methylation patterns in primary cancers, as suggested in previous studies (Suzuki et al., 2002; Sato et al., 2003b, d) . We were able to confirm that the hypomethylation patterns of maspin and S100P identified in pancreatic cancer cell lines were also present in xenografted and microdissected primary pancreatic cancers.
Identification of genes affected by aberrant hypomethylation may have important therapeutic implications because this epigenetic change has considered a reversible biological modification. For example, a recent study demonstrated that treatment of hepatocellular carcinoma cells with a methylated oligonucleotide led to specific induction of de novo methylation at hypomethylated IGF2 promoter, inhibited its mRNA expression, and markedly prolonged survival of nude mice with an implanted tumor (Yao et al., 2003) . This study suggests that some genes hypomethylated in a cancer-specific manner may represent potential targets for the development of novel cancer treatment. On the other hand, cancer therapies using inhibitors for DNA methylation and histone deacetylation could result in reactivation of cancer-promoting genes in a subset of tumors where these genes are repressed by DNA methylation (Guo et al., 2002; Pakneshan et al., 2003; Sato et al., 2003c) .
Maspin is a unique member of serine protease inhibitor, which has been considered a tumor-suppressor protein because of its property to inhibit motility, invasion, and metastasis of breast and prostate cancers (Zou et al., 1994; Sheng et al., 1996) . The expression of maspin is restricted to certain type of epithelial cells, including those of the breast, whereas the expression is lost in many breast cancers (Zou et al., 1994) . In contrast to the expression pattern in the breast, maspin is not expressed in normal pancreatic epithelium but is overexpressed in pancreatic cancer cell lines and primary pancreatic adenocarcinoma tissues (Maass et al., 2001) . The biological significance of maspin overexpression in pancreatic cancer is unknown. Based on the findings that maspin overexpression was also observed in other cancers including ovarian carcinoma (Sood et al., 2002) , it is likely that maspin may play a different role in different cancer types. Previous studies have shown that DNA methylation is associated with the silencing of maspin expression in breast cancer cells (Domann et al., 2000; Maass et al., 2002) . Recently, Futscher et al. (2002) demonstrated that cell-type-restricted maspin expression is regulated by DNA methylation. We provide the first evidence that maspin is methylated in normal pancreatic epithelium, but is hypomethylated in the vast majority of pancreatic cancers. Our present findings further support the association between DNA methylation and the transcriptional regulation of this gene. Notably, maspin is also known to be regulated by tumor-suppressor p53 (Zou et al., 2000) , and a recent report have shown that treatment of breast cancer cells harboring mutant p53 with 5-aza-dC in combination with restoration of wild-type p53 results in a synergistic reactivation of maspin (Oshiro et al., 2003) . These findings suggest that genetic and epigenetic factors may be cooperatively involved in the transcriptional regulation of maspin in cancer.
Several lines of evidence have implicated S100P in cancer development and progression. Global gene expression studies using cDNA and oligonucleotide microarrays identified S100P as one of the most highly expressed genes in pancreatic cancer (Iacobuzio-Donahue et al., 2002 Logsdon et al., 2003) . Overexpression of S100P has been shown to be associated with immortalization of human breast epithelial cells (Guerreiro Da Silva et al., 2000) and with progression of prostate cancer (Mousses et al., 2002) . It has been recently demonstrated that ectopic overexpression of the proto-oncogene ERBB2 (HER2/neu) in mammary luminal epithelial cells results in upregulated expression of S100P, suggesting that S100P may play a role in ERBB2-related oncogenesis (Mackay et al., 2003) . Furthermore, S100P has been shown to bind to and activate ezrin, a membrane-cytoskeleton linker required for cell morphogenesis, motility, and survival, raising a possibility that S100P may play a role in cancer invasion and metastasis (Koltzscher et al., 2003) . Thus, it is likely that overexpression of S100P in association with aberrant hypomethylation may be involved in pancreatic neoplastic progression. Our finding of a high prevalence of S100P hypomethylation in pancreatic cancer also suggests that S100P could be a novel therapeutic target for pancreatic cancer.
In the present study, we provide evidence for tumortype-specific hypomethylation patterns by comparing the methylation status of four genes between pancreatic and breast cancer cell lines. We noted a significant difference in the methylation patterns of maspin, TFF2, and lipocalin2 between these two cancer types. These results are similar to observations of aberrant hypermethylation at genetic loci that have demonstrated cancer-type specificity (Costello et al., 2000; Esteller et al., 2001) . Our findings raise the possibility that there is a difference in the propensity to develop DNA hypomethylation among cancer types. It is also possible Hypomethylation of maspin and S100P in pancreatic cancer N Sato et al that each cancer type targets different loci for hypomethylation. The mechanism for gene-specific hypomethylation is unknown, but recent studies have suggested that methylation changes in cancer may occur, at least in some cases, as a consequence of genetic or other events that alter the transcriptional activities of affected promoters (Di Croce et al., 2002; Bachman et al., 2003) . In summary, we have identified maspin and S100P as aberrantly hypomethylated in pancreatic cancer using an oligonucleotide-microarray-based approach. Further analysis of genes overexpressed in cancer is expected to lead to the discovery of novel target genes affected by this epigenetic alteration.
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